Business Description
Quince Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US22053A1079
Total Employee Number:
38Description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 44.74 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 13 | |||||
3-Year EPS without NRI Growth Rate | 7.3 | |||||
3-Year FCF Growth Rate | 14.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.59 | |||||
9-Day RSI | 40.64 | |||||
14-Day RSI | 39.67 | |||||
3-1 Month Momentum % | -33.24 | |||||
6-1 Month Momentum % | -96.62 | |||||
12-1 Month Momentum % | -94.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.92 | |||||
Quick Ratio | 2.92 | |||||
Cash Ratio | 2.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.5 | |||||
Shareholder Yield % | -182.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1457.43 | |||||
ROA % | -36.36 | |||||
ROIC % | -64.23 | |||||
3-Year ROIIC % | 0.53 | |||||
ROC (Joel Greenblatt) % | -4736.6 | |||||
ROCE % | -67.42 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.77 | |||||
Price-to-Tangible-Book | 0.77 | |||||
EV-to-EBIT | 0.01 | |||||
EV-to-EBITDA | 0.01 | |||||
EV-to-Forward-Revenue | 7.37 | |||||
EV-to-FCF | 0.02 | |||||
| Price-to-Net-Current-Asset-Value | 0.82 | |||||
| Price-to-Net-Cash | 1.67 | |||||
Earnings Yield (Greenblatt) % | No Debt | |||||
FCF Yield % | -231.97 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QNCX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quince Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -212.4 | ||
| Beta | 1.0619 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 169.13 | ||
| 14-Day RSI | 39.67 | ||
| 14-Day ATR ($) | 1.604209 | ||
| 20-Day SMA ($) | 18.1913 | ||
| 12-1 Month Momentum % | -94.89 | ||
| 52-Week Range ($) | 15.1 - 909.98 | ||
| Shares Outstanding (Mil) | 0.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quince Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quince Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 29 days | ||
| 0.05:1 Stock Split | 2026-06-30 | 18.41 (-1.01%) | ||
| General meeting for 2026 | 2026-06-11 10:00 | 18.20 (-7.14%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 25.60 (+0.00%) | ||
| 0.1:1 Stock Split | 2026-04-13 | 27.26 (+18.73%) | ||
| Annual report for 2025 | 2026-04-10 | 24.74 (-1.67%) | ||
| Citizens Equity Analyst Hosted KOL Call – Ataxia-Telangiectasia Unmet Need and Opportunity | 2026-01-07 10:00 | 556.00 (-2.80%) | ||
| Virtual Lunch with LifeSci Featuring Quince Therapeutics | 2025-12-16 13:00 | 754.00 (-11.29%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-03 10:30 | 676.00 (+6.62%) |
Show
Entries
Quince Therapeutics Inc Frequently Asked Questions
What is Quince Therapeutics Inc(QNCX)'s stock price today?
The current price of QNCX is $17.48. The 52 week high of QNCX is $909.98 and 52 week low is $15.10.
When is next earnings date of Quince Therapeutics Inc(QNCX)?
The next earnings date of Quince Therapeutics Inc(QNCX) is 2026-08-11 Est..
Does Quince Therapeutics Inc(QNCX) pay dividends? If so, how much?
Quince Therapeutics Inc(QNCX) does not pay dividend.
Guru Commentaries on NAS:QNCX
No articles.
Press Release
Articles on Quince Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers